Cardiac Troponin Structure-function and the Influence of Hypertrophic Cardiomyopathy Associated Mutations on Modulation of Contractility

Overview

Journal Arch Biochem Biophys

Publisher Elsevier

Specialties Biochemistry
Biophysics

Date 2016 Feb 7

PMID 26851561

Citations 27

Authors

Yuanhua Cheng

Michael Regnier

Affiliations

Soon will be listed here.

Abstract

Cardiac troponin (cTn) acts as a pivotal regulator of muscle contraction and relaxation and is composed of three distinct subunits (cTnC: a highly conserved Ca(2+) binding subunit, cTnI: an actomyosin ATPase inhibitory subunit, and cTnT: a tropomyosin binding subunit). In this mini-review, we briefly summarize the structure-function relationship of cTn and its subunits, its modulation by PKA-mediated phosphorylation of cTnI, and what is known about how these properties are altered by hypertrophic cardiomyopathy (HCM) associated mutations of cTnI. This includes recent work using computational modeling approaches to understand the atomic-based structural level basis of disease-associated mutations. We propose a viewpoint that it is alteration of cTnC-cTnI interaction (rather than the Ca(2+) binding properties of cTn) per se that disrupt the ability of PKA-mediated phosphorylation at cTnI Ser-23/24 to alter contraction and relaxation in at least some HCM-associated mutations. The combination of state of the art biophysical approaches can provide new insight on the structure-function mechanisms of contractile dysfunction resulting cTnI mutations and exciting new avenues for the diagnosis, prevention, and even treatment of heart diseases.

Citing Articles

An FDA-approved drug structurally and phenotypically corrects the K210del mutation in genetic cardiomyopathy models.

Wang P, Ahmed M, Nguyen N, Menendez-Montes I, Hsu C, Farag A J Clin Invest. 2025; 135(4).

PMID: 39959972 PMC: 11827848. DOI: 10.1172/JCI174081.

Data-Driven Insights into the Association Between Oxidative Stress and Calcium-Regulating Proteins in Cardiovascular Disease.

Panday N, Sigdel D, Adam I, Ramirez J, Verma A, Eranki A Antioxidants (Basel). 2024; 13(11).

PMID: 39594561 PMC: 11590986. DOI: 10.3390/antiox13111420.

Hyperactive mTORC1/4EBP1 signaling dysregulates proteostasis and accelerates cardiac aging.

Zarzycka W, Kobak K, King C, Peelor 3rd F, Miller B, Chiao Y Geroscience. 2024; .

PMID: 39379739 DOI: 10.1007/s11357-024-01368-w.

Focus on cardiac troponin complex: From gene expression to cardiomyopathy.

Ragusa R, Caselli C Genes Dis. 2024; 11(6):101263.

PMID: 39211905 PMC: 11357864. DOI: 10.1016/j.gendis.2024.101263.

Glutamate 139 of tropomyosin is critical for cardiac thin filament blocked-state stabilization.

Barry M, Rynkiewicz M, Pavadai E, Viana A, Lehman W, Moore J J Mol Cell Cardiol. 2024; 188:30-37.

PMID: 38266978 PMC: 11654406. DOI: 10.1016/j.yjmcc.2024.01.004.

References

Saggin L, Gorza L, Ausoni S, Schiaffino S . Troponin I switching in the developing heart. J Biol Chem. 1989; 264(27):16299-302. View

Pinto J, Reynaldo D, Parvatiyar M, Dweck D, Liang J, Jones M . Strong cross-bridges potentiate the Ca(2+) affinity changes produced by hypertrophic cardiomyopathy cardiac troponin C mutants in myofilaments: a fast kinetic approach. J Biol Chem. 2010; 286(2):1005-13. PMC: 3020707. DOI: 10.1074/jbc.M110.168583. View

Hinkle A, Tobacman L . Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem. 2002; 278(1):506-13. DOI: 10.1074/jbc.M209194200. View

Hanft L, Biesiadecki B, McDonald K . Length dependence of striated muscle force generation is controlled by phosphorylation of cTnI at serines 23/24. J Physiol. 2013; 591(18):4535-47. PMC: 3784197. DOI: 10.1113/jphysiol.2013.258400. View

Korte F, Feest E, Razumova M, Tu A, Regnier M . Enhanced Ca2+ binding of cardiac troponin reduces sarcomere length dependence of contractile activation independently of strong crossbridges. Am J Physiol Heart Circ Physiol. 2012; 303(7):H863-70. PMC: 3469702. DOI: 10.1152/ajpheart.00395.2012. View

Howarth J, FINLEY N, Abusamhadneh E, Gaponenko V, Brito R, Solaro R . Solution structures of the C-terminal domain of cardiac troponin C free and bound to the N-terminal domain of cardiac troponin I. Biochemistry. 1999; 38(26):8313-22. DOI: 10.1021/bi9902642. View

Chandra M, Tschirgi M, Tardiff J . Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ Physiol. 2005; 289(5):H2112-9. DOI: 10.1152/ajpheart.00571.2005. View

Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C . Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003; 107(17):2227-32. DOI: 10.1161/01.CIR.0000066323.15244.54. View

Takeda S, Yamashita A, Maeda K, Maeda Y . Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature. 2003; 424(6944):35-41. DOI: 10.1038/nature01780. View

10.

Lindhout D, Li M, Schieve D, Sykes B . Effects of T142 phosphorylation and mutation R145G on the interaction of the inhibitory region of human cardiac troponin I with the C-domain of human cardiac troponin C. Biochemistry. 2002; 41(23):7267-74. DOI: 10.1021/bi020100c. View

11.

Kruger M, Zittrich S, Redwood C, Blaudeck N, James J, Robbins J . Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-relaxation cycle in isolated cardiac myofibrils. J Physiol. 2005; 564(Pt 2):347-57. PMC: 1464436. DOI: 10.1113/jphysiol.2004.079095. View

12.

Liang J, Kazmierczak K, Rojas A, Wang Y, Szczesna-Cordary D . The R21C Mutation in Cardiac Troponin I Imposes Differences in Contractile Force Generation between the Left and Right Ventricles of Knock-In Mice. Biomed Res Int. 2015; 2015:742536. PMC: 4415466. DOI: 10.1155/2015/742536. View

13.

Pi Y, Kemnitz K, Zhang D, Kranias E, Walker J . Phosphorylation of troponin I controls cardiac twitch dynamics: evidence from phosphorylation site mutants expressed on a troponin I-null background in mice. Circ Res. 2002; 90(6):649-56. DOI: 10.1161/01.res.0000014080.82861.5f. View

14.

Heeley D, Golosinska K, Smillie L . The effects of troponin T fragments T1 and T2 on the binding of nonpolymerizable tropomyosin to F-actin in the presence and absence of troponin I and troponin C. J Biol Chem. 1987; 262(21):9971-8. View

15.

Nixon B, Thawornkaiwong A, Jin J, Brundage E, Little S, Davis J . AMP-activated protein kinase phosphorylates cardiac troponin I at Ser-150 to increase myofilament calcium sensitivity and blunt PKA-dependent function. J Biol Chem. 2012; 287(23):19136-47. PMC: 3365946. DOI: 10.1074/jbc.M111.323048. View

16.

Harada K, Potter J . Familial hypertrophic cardiomyopathy mutations from different functional regions of troponin T result in different effects on the pH and Ca2+ sensitivity of cardiac muscle contraction. J Biol Chem. 2004; 279(15):14488-95. DOI: 10.1074/jbc.M309355200. View

17.

Gomes A, Harada K, Potter J . A mutation in the N-terminus of troponin I that is associated with hypertrophic cardiomyopathy affects the Ca(2+)-sensitivity, phosphorylation kinetics and proteolytic susceptibility of troponin. J Mol Cell Cardiol. 2005; 39(5):754-65. DOI: 10.1016/j.yjmcc.2005.05.013. View

18.

Solaro R, Rosevear P, Kobayashi T . The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2007; 369(1):82-7. PMC: 2365727. DOI: 10.1016/j.bbrc.2007.12.114. View

19.

Rani D, Nallari P, Priyamvada S, Narasimhan C, Singh L, Thangaraj K . High prevalence of Arginine to Glutamine substitution at 98, 141 and 162 positions in Troponin I (TNNI3) associated with hypertrophic cardiomyopathy among Indians. BMC Med Genet. 2012; 13:69. PMC: 3495047. DOI: 10.1186/1471-2350-13-69. View

20.

Tester D, Ackerman M . Cardiomyopathic and channelopathic causes of sudden unexplained death in infants and children. Annu Rev Med. 2008; 60:69-84. DOI: 10.1146/annurev.med.60.052907.103838. View